NASDAQ:ICLR - Icon Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$133.50 -2.71 (-1.99 %)
(As of 12/14/2018 04:00 PM ET)
Previous Close$133.50
Today's Range$132.56 - $137.87
52-Week Range$101.22 - $155.33
Volume221,181 shs
Average Volume331,395 shs
Market Capitalization$7.37 billion
P/E Ratio24.77
Dividend YieldN/A
Beta0.55
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company's clinical development services include product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, clinical research center, investigator site, patient recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety and risk-based monitoring, clinical data management, strategic analysis and data operation, regulatory consulting, and medical reporting and pharmacovigilance services. Its clinical development services also comprise interactive response technologies, electronic endpoint adjudication, medical imaging, adaptive trial design and execution, medical device and biosimilar trial, functional, strategic resourcing, sample analyses, safety testing, microbiology, custom flow cytometry, biomarker development, bioanalysis, immunoassay development, patient registries, outcomes research, health economics, market access and commercialization, drug price consulting, and healthcare and scientific communication services, as well as research trials for the U.S. government agencies, electronic transmission of test results, and electronic patient reported outcomes. The company was founded in 1990 and is headquartered in Dublin, Ireland.

Receive ICLR News and Ratings via Email

Sign-up to receive the latest news and ratings for ICLR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICLR
Previous Symbol
CUSIPN/A
Phone353-1291-2000

Debt

Debt-to-Equity Ratio0.26
Current Ratio2.17
Quick Ratio2.17

Price-To-Earnings

Trailing P/E Ratio24.77
Forward P/E Ratio21.96
P/E Growth1.95

Sales & Book Value

Annual Sales$1.76 billion
Price / Sales4.11
Cash Flow$6.4680 per share
Price / Cash Flow20.64
Book Value$22.02 per share
Price / Book6.06

Profitability

EPS (Most Recent Fiscal Year)$5.39
Net Income$281.48 million
Net Margins12.88%
Return on Equity26.08%
Return on Assets14.62%

Miscellaneous

Employees13,250
Outstanding Shares54,080,000
Market Cap$7.37 billion
OptionableOptionable

Icon (NASDAQ:ICLR) Frequently Asked Questions

What is Icon's stock symbol?

Icon trades on the NASDAQ under the ticker symbol "ICLR."

How were Icon's earnings last quarter?

Icon Plc (NASDAQ:ICLR) posted its quarterly earnings results on Wednesday, October, 24th. The medical research company reported $1.54 earnings per share for the quarter, hitting the Zacks' consensus estimate of $1.54. The medical research company earned $655.02 million during the quarter, compared to the consensus estimate of $654.66 million. Icon had a net margin of 12.88% and a return on equity of 26.08%. View Icon's Earnings History.

When is Icon's next earnings date?

Icon is scheduled to release their next quarterly earnings announcement on Thursday, February 21st 2019. View Earnings Estimates for Icon.

What price target have analysts set for ICLR?

9 analysts have issued 1-year price objectives for Icon's stock. Their predictions range from $126.00 to $157.00. On average, they expect Icon's share price to reach $146.1250 in the next year. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Icon.

What is the consensus analysts' recommendation for Icon?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icon in the last year. There are currently 1 sell rating, 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Icon.

Has Icon been receiving favorable news coverage?

Press coverage about ICLR stock has been trending somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Icon earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned media headlines about the medical research company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the near term.

Who are some of Icon's key competitors?

Who are Icon's key executives?

Icon's management team includes the folowing people:
  • Dr. Steven A. Cutler, CEO & Director (Age 58)
  • Mr. Brendan Brennan, Chief Financial Officer (Age 39)
  • Jonathan Curtain, VP of Corp. Fin. & Investor Relations
  • Mr. Thomas O'Leary, Chief Information Officer
  • Mr. Diarmaid Cunningham, Chief Admin. Officer, Gen. Counsel, Exec. VP & Company Sec. (Age 43)

Who are Icon's major shareholders?

Icon's stock is owned by many different of institutional and retail investors. Top institutional shareholders include WCM Investment Management CA (9.25%), Alliancebernstein L.P. (4.97%), Clearbridge Investments LLC (4.09%), Acadian Asset Management LLC (4.03%), Earnest Partners LLC (3.97%) and Renaissance Technologies LLC (3.49%).

Which major investors are selling Icon stock?

ICLR stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Alliancebernstein L.P., Partner Fund Management L.P., Baird Financial Group Inc., Royce & Associates LP, Renaissance Technologies LLC, Canada Pension Plan Investment Board and Wasatch Advisors Inc..

Which major investors are buying Icon stock?

ICLR stock was acquired by a variety of institutional investors in the last quarter, including WCM Investment Management CA, Clearbridge Investments LLC, Bank of New York Mellon Corp, Massachusetts Financial Services Co. MA, The Manufacturers Life Insurance Company , Rehmann Capital Advisory Group, Comgest Global Investors S.A.S. and Dorsey Wright & Associates.

How do I buy shares of Icon?

Shares of ICLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Icon's stock price today?

One share of ICLR stock can currently be purchased for approximately $133.50.

How big of a company is Icon?

Icon has a market capitalization of $7.37 billion and generates $1.76 billion in revenue each year. The medical research company earns $281.48 million in net income (profit) each year or $5.39 on an earnings per share basis. Icon employs 13,250 workers across the globe.

What is Icon's official website?

The official website for Icon is http://www.iconplc.com.

How can I contact Icon?

Icon's mailing address is SOUTH COUNTY BUSINESS PARK LEOPARDSTOWN, DUBLIN L2, 00000. The medical research company can be reached via phone at 353-1291-2000.


MarketBeat Community Rating for Icon (NASDAQ ICLR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  434 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  754
MarketBeat's community ratings are surveys of what our community members think about Icon and other stocks. Vote "Outperform" if you believe ICLR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICLR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel